Trial Profile
HEPLISAV-B Pregnancy Registry: An Observational Study on the Safety of HEPLISAV-B Exposure in Pregnant Women and Their Offspring
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2023
Price :
$35
*
At a glance
- Drugs Adjuvanted Hepatitis-B vaccine (Recombinant)-Dynavax (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Acronyms HBV-27
- Sponsors Dynavax Technologies
- 15 Sep 2023 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 15 Sep 2023 Planned primary completion date changed from 1 Aug 2023 to 1 Sep 2024.
- 15 Sep 2023 Status changed from recruiting to active, no longer recruiting.